AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Phase 1AH-008Positive

AI Analysis

Summary

AnHorn Medicines announced successful first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate for prevention of chemotherapy-induced peripheral neuropathy.

Clinical Trial Data

Phase

Phase I

Outcome Details

First subject first dose (FSFD) completed

Importance:5/10

Sentiment:

0.70

Phase 1CIPNNeuroprotectionFirst-in-classClinical milestone

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on July 23, 2026 2:00 PM

Read Original